Biohaven

New Haven, United States Founded: 2022 • Age: 4 yrs Acquired By Pfizer
Therapeutics for neurological and neuropsychiatric diseases are developed.
Request Access

About Biohaven

Biohaven is a company based in New Haven (United States) founded in 2022 was acquired by Pfizer in October 2022.. The company has 256 employees as of December 31, 2024. Biohaven offers products and services including Nurtec ODT and Zavzpret. Biohaven operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.

  • Headquarter New Haven, United States
  • Employees 256 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biohaven Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0
    0
    as on Dec 31, 2024
  • Net Profit
    $-846.42 M
    -107.37
    as on Dec 31, 2024
  • EBITDA
    $-881.19 M
    -103.66
    as on Dec 31, 2024
  • Latest Funding Round
    $250 M (USD), Post-IPO

    Apr 28, 2025

  • Investors
    Pfizer

    & 1 more

  • Employee Count
    256

    as on Dec 31, 2024

  • Acquired by
    Pfizer

    (Oct 04, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Biohaven

Biohaven is a publicly listed company on the NYSE with ticker symbol BHVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NYSE · Ticker: BHVN . Sector: Health technology · USA

Products & Services of Biohaven

Biohaven offers a comprehensive portfolio of products and services, including Nurtec ODT and Zavzpret. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Oral therapy for acute and preventive migraine relief.

Nasal spray for treating migraine attacks effectively.

People of Biohaven
Headcount 500-1000
Employee Profiles 155
Board Members and Advisors 6
Employee Profiles
People
Jim Mather
VP, Clinical Operations
People
Debbie Connell
Neuroscience Sales Specialist
People
Robert Croop
Chief Development Officer, Neurology
People
Jennifer Madonia
Senior Medical Director

Unlock access to complete

Board Members and Advisors
people
Gregory H. Bailey
Director
people
John W. Childs
Director
people
Robert J. Hugin
Director
people
Michael T. Heffernan
Lead Independent Director

Unlock access to complete

Funding Insights of Biohaven

  • Total Funding
  • Total Rounds 1
  • Last Round Post-IPO — $250.0M
  • First Round

    (28 Apr 2025)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2025 Amount Post-IPO - Biohaven Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Biohaven

Biohaven has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer and Oberland Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
Founded Year Domain Location
Pharmaceutical products for treating multiple diseases are provided.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Biohaven

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Biohaven

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biohaven Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Biohaven

Biohaven operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Drugs for CNS disorders are developed and advanced.
domain founded_year HQ Location
Developer of therapeutic solutions for the treatment of diabetes
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Therapies for neurological and neuropsychiatric diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Biohaven

Frequently Asked Questions about Biohaven

When was Biohaven founded?

Biohaven was founded in 2022 and raised its 1st funding round 3 years after it was founded.

Where is Biohaven located?

Biohaven is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.

How many employees does Biohaven have?

As of Dec 31, 2024, the latest employee count at Biohaven is 256.

What does Biohaven do?

Biohaven was founded in 2022 and is headquartered in New Haven, United States. Focus is placed on the development of therapeutics targeting neurological and neuropsychiatric conditions within the biotechnology sector. Proprietary platforms are utilized, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder, spinocerebellar ataxia, and myostatin inhibition for neuromuscular diseases. Operations emphasize drug discovery and clinical advancement in these areas.

Who are the top competitors of Biohaven?

Biohaven's top competitors include Jazz Pharmaceuticals, Biohaven Pharmaceutical and Sana Biotechnology.

What products or services does Biohaven offer?

Biohaven offers Nurtec ODT and Zavzpret.

Is Biohaven publicly traded?

Yes, Biohaven is publicly traded on NYSE under the ticker symbol BHVN.

Who are Biohaven's investors?

Biohaven has 2 investors. Key investors include Pfizer, and Oberland Capital.

What is Biohaven's ticker symbol?

The ticker symbol of Biohaven is BHVN on NYSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available